Recall: Legacy Losartan Potassium USP
On 2019-04-24, the FDA announced that Legacy Pharmaceutical Packaging is conducting a recall on Losartan Potassium USP due to a possible . The recalled products were sold under the brand name(s) Legacy during an unspecified time period throughout the regions shown in the map below.
In recent months, there have been 9 drugs recalls due to potential elevated impurity, including losartan potassium tablets, usp, 25mg, 50mg, and 100mg, losartan potassium tablets, usp, 50mg and more. Additionally, there have been 19 drug and medical device recalls due to other health hazards as well as 84 food recalls.
Company Contact Information:
Name: Legacy Pharmaceutical Packaging
Do you work for a company involved with this recall? Contact us to learn how you can control data, information and ads shown on this page.
Detailed Recall Information
Regions Where Sold: Nationwide
Product Description: Losartan Potassium USP
Brand Name(s): Legacy
Reason for Recall: N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity
Official Recall Date: 2019-04-24
Additional information provided by the FDA.gov:
Legacy Pharmaceutical Packaging, LLC is expanding its consumer-level recall of 3 repackaged lots Losartan Tablets USP 50mg to include one additional lot. This recall was prompted due to Torrent Pharmaceuticals LTD issuing a Voluntary Nationwide Recall of Losartan Tablets, USP, due to the detection of trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, (API manufacturer). Read More.
More information may be available at FDA.gov
Latest Safety Recalls
Select image for details, including additional styles.
Sources may include Food & Drug Administration (FDA), United States Department of Agriculture (USDA), Health Canada and companies involved with this or a related recall.